BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27069181)

  • 1. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
    Kanekiyo S; Takeda S; Nakajima M; Nishiyama M; Kitahara M; Shindou Y; Michihisa I; Abe T; Yoshino S; Hazama S; Nagano H
    Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting.
    Osaka Y; Takagi Y; Hoshino S; Tachibana S; Tsuchida A; Aoki T
    Dis Esophagus; 2006; 19(6):473-6. PubMed ID: 17069591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
    Fujita Y; Hiramatsu M; Kawai M; Sumiyoshi K; Nishimura H; Tanigawa N
    Dis Esophagus; 2008; 21(6):496-501. PubMed ID: 18840134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer].
    Irino T; Egawa T; Kenmochi T; Ito Y; Mihara K; Okamura A; Eto E; Inaba Y; Murakawa M; Nagashima A
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2401-4. PubMed ID: 22202395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
    Yamazaki K; Hironaka S; Boku N; Yasui H; Fukutomi A; Yoshino T; Onozawa Y; Hasuike N; Inui T; Yamaguchi Y; Ono H
    Int J Clin Oncol; 2008 Apr; 13(2):150-5. PubMed ID: 18463960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma.
    Matsumoto H; Hirabayashi Y; Kubota H; Murakami H; Higashida M; Haruma K; Hiratsuka J; Nakamura M; Hirai T
    Anticancer Res; 2012 May; 32(5):1827-31. PubMed ID: 22593469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
    Jin J; Xu X; Wang F; Yan G; Liu J; Lu W; Li X; Tucker SJ; Zhong B; Cao Z; Wang D
    J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
    Akutsu Y; Shuto K; Kono T; Uesato M; Hoshino I; Shiratori T; Miyazawa Y; Isozaki Y; Akanuma N; Matsubara H
    Hepatogastroenterology; 2012 Oct; 59(119):2095-8. PubMed ID: 22328303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An elderly hemodialytic case of recurrent esophageal cancer given combination chemotherapy with docetaxel and nedaplatin who showed temporal relief of swallowing disturbance].
    Miura T; Hosojima Y; Nakamura J; Yamada S; Nakazawa Y; Ozeki Y; Miura T; Yanagi M; Yamazaki H; Takahashi T
    Gan To Kagaku Ryoho; 2010 May; 37(5):883-5. PubMed ID: 20495320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
    Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J
    Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.
    Nakajima Y; Suzuki T; Haruki S; Ogiya K; Kawada K; Nishikage T; Nagai K; Kawano T
    Hepatogastroenterology; 2008; 55(86-87):1631-5. PubMed ID: 19102357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
    Miyazaki T; Ojima H; Fukuchi M; Sakai M; Sohda M; Tanaka N; Suzuki S; Ieta K; Saito K; Sano A; Yokobori T; Inose T; Nakajima M; Kato H; Kuwano H
    Ann Surg Oncol; 2015 Oct; 22(11):3653-8. PubMed ID: 25691281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
    Yoshioka T; Sakayori M; Kato S; Chiba N; Miyazaki S; Nemoto K; Shibata H; Shimodaira H; Ohtsuka K; Kakudo Y; Sakata Y; Ishioka C
    Int J Clin Oncol; 2006 Dec; 11(6):454-60. PubMed ID: 17180514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
    Tanaka Y; Yoshida K; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K
    Cancer Sci; 2016 Jun; 107(6):764-72. PubMed ID: 27061001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of combination chemotherapy with docetaxel and nedaplatin for esophageal cancer].
    Kawada J; Iwase K; Deguchi K; Higashi S; Deguchi T; Matsuda C; Tamagawa H; Omori K; Nishikawa K; Nomura M; Takagi M; Fukui A; Tanaka Y
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2095-7. PubMed ID: 23267988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of combination chemotherapy with docetaxel and nedaplatin in patients with advanced or recurrent esophageal cancer].
    Funaki H; Miura S; Morioka E; Kaida D; Ohnishi T; Ohno Y; Tomita Y; Noguchi M; Fujita H; Kinami S; Nakano Y; Ueda N; Kosaka T
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2384-6. PubMed ID: 25731531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer.
    Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):853-7. PubMed ID: 23306309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
    Tanaka T; Fujita H; Sueyoshi S; Tanaka Y; Sasahara H; Mori N; Nagano T; Yamana H; Shirouzu K
    Chemotherapy; 2007; 53(6):449-53. PubMed ID: 17952006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.